Alluvi, formerly BI 4744, presents a significant advance in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP targets demonstrates compelling effectiveness in patient trials, potentially https://social-galaxy.com/story7726928/alluvi-a-in-depth-dive-into-retatrutide-s-prospects